Principia Wealth Advisory’s Alnylam Pharmaceuticals ALNY Stock Holding History

Principia Wealth Advisory’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.01K	Buy	10 +5	+100%	+$1.51K	﹤0.01%	483
2026 Q1	$1.65K	Sell	5 -1	-17%	-$340	﹤0.01%	566
2025 Q4	$2.39K	Buy	6 +1	+20%	+$443	﹤0.01%	417
2025 Q3	$2.28K	Hold	5	–	–	﹤0.01%	410
2025 Q2	$1.63K	Buy	5 +2	+67%	+$553	﹤0.01%	432
2025 Q1	$730	Sell	3 -1	-25%	-$257	﹤0.01%	475
2024 Q4	$941	Buy	+4	New	+$1.05K	﹤0.01%	382

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Principia Wealth Advisory's ALNY Position: Q2 2026 in Review

Principia Wealth Advisory increased its Alnylam Pharmaceuticals (ALNY) stake by 100% in Q2 2026, buying an estimated $1.51K and bringing the position to 10 shares worth $3.01K. The position accounts for ﹤0.01% of the portfolio, ranked #483.

Principia Wealth Advisory first reported a position in ALNY in Q4 2024 and has held it in 7 quarters since. 788 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

Principia Wealth Advisory held 10 shares of Alnylam Pharmaceuticals worth $3.01K as of Q2 2026.
Principia Wealth Advisory bought 5 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $1.51K.
Alnylam Pharmaceuticals made up ﹤0.01% of Principia Wealth Advisory's portfolio in Q2 2026, its #483 holding.
Principia Wealth Advisory first reported a position in Alnylam Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
788 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on Principia Wealth Advisory's 13F filing for Q2 2026, filed 26 Aug 2026.